Pancreatic Adenocarcinoma, version 2.2012: featured updates to the NCCN Guidelines

The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Pancreatic Adenocarcinoma discuss the workup and management of tumors of the exocrine pancreas. These NCCN Guidelines Insights provide a summary and explanation of major changes to the 2012 NCCN Guidelines for Pancreatic Adenoca...

Full description

Saved in:
Bibliographic Details
Published inJournal of the National Comprehensive Cancer Network Vol. 10; no. 6; p. 703
Main Authors Tempero, Margaret A, Arnoletti, J Pablo, Behrman, Stephen W, Ben-Josef, Edgar, Benson, 3rd, Al B, Casper, Ephraim S, Cohen, Steven J, Czito, Brian, Ellenhorn, Joshua D I, Hawkins, William G, Herman, Joseph, Hoffman, John P, Ko, Andrew, Komanduri, Srinadh, Koong, Albert, Ma, Wen Wee, Malafa, Mokenge P, Merchant, Nipun B, Mulvihill, Sean J, Muscarella, 2nd, Peter, Nakakura, Eric K, Obando, Jorge, Pitman, Martha B, Sasson, Aaron R, Tally, Anitra, Thayer, Sarah P, Whiting, Samuel, Wolff, Robert A, Wolpin, Brian M, Freedman-Cass, Deborah A, Shead, Dorothy A
Format Journal Article
LanguageEnglish
Published United States 01.06.2012
Subjects
Online AccessGet more information

Cover

Loading…
More Information
Summary:The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Pancreatic Adenocarcinoma discuss the workup and management of tumors of the exocrine pancreas. These NCCN Guidelines Insights provide a summary and explanation of major changes to the 2012 NCCN Guidelines for Pancreatic Adenocarcinoma. The panel made 3 significant updates to the guidelines: 1) more detail was added regarding multiphase CT techniques for diagnosis and staging of pancreatic cancer, and pancreas protocol MRI was added as an emerging alternative to CT; 2) the use of a fluoropyrimidine plus oxaliplatin (e.g., 5-FU/leucovorin/oxaliplatin or capecitabine/oxaliplatin) was added as an acceptable chemotherapy combination for patients with advanced or metastatic disease and good performance status as a category 2B recommendation; and 3) the panel developed new recommendations concerning surgical technique and pathologic analysis and reporting.
ISSN:1540-1413
DOI:10.6004/jnccn.2012.0073